Skip to main content

Advertisement

SpringerLink
Log in

New Options for the Adjuvant Treatment of Cutaneous Melanoma?

  • Melanoma (KB Kim, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

High-dose interferon is the current standard of care for the adjuvant treatment of high-risk cutaneous melanoma. Despite numerous clinical trials using interferon in a variety of doses and schedules, none have demonstrated a meaningful clinical improvement relative to standard high-dose interferon. Recently however, a phase III trial using biochemotherapy demonstrated a superior relapse-free survival benefit over standard interferon. In addition, several agents approved for use in metastatic melanoma are being investigated in the adjuvant setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am. 2011;20(1):1–17.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol. 1996;14(1):7–17.

    PubMed  CAS  Google Scholar 

  4. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10(5):1670–7.

    Article  PubMed  CAS  Google Scholar 

  5. Gogas H, Bafaloukos D, Ioannovich J, et al. Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year—a Hellenic Cooperative Oncology Group study. Anticancer Res. 2004;24(3b):1947–52.

    PubMed  CAS  Google Scholar 

  6. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444–58.

    PubMed  CAS  Google Scholar 

  7. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19(9):2370–80.

    PubMed  CAS  Google Scholar 

  8. Gogas H, Dafni U, Bafaloukos D, Polyzos A, Kokkalis G, Kalofonos HP, et al. A randomized phase III trial of 1 month versus 1 year adjuvant high-dose Interferon alfa-2b in patients with resected high risk melanoma. J Clin Oncol. 2007;25(18 Suppl):8505.

    Google Scholar 

  9. Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005;366(9492):1189–96.

    Article  PubMed  CAS  Google Scholar 

  10. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372(9633):117–26.

    Article  PubMed  CAS  Google Scholar 

  11. Eggermont AM, Suciu S, Testori A, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;30(31):3810–8.

    Article  PubMed  CAS  Google Scholar 

  12. Kim KB, Legha SS, Gonzalez R, et al. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009;19(1):42–9.

    Article  PubMed  CAS  Google Scholar 

  13. Flaherty LE, Moon J, Atkins MB, Tuthill R, Thompson JA, Vetto JT, et al. Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC, plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): an intergroup study of CALGB, COG, ECOG, and SWOG. J Clin Oncol. 2012;30(15 Suppl):8504.

    Google Scholar 

  14. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Fadaki N, Cardona-Huerta S, Martineau L, et al. Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib. BMJ Case Rep. 2012. doi:10.1136/bcr-2012-007034.

    PubMed  Google Scholar 

  17. Koers K, Francken AB, Haanen JB, Woerdeman LA, van der Hage JA. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma. J Clin Oncol. 2013;31(16):e251–3.

    Article  PubMed  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Amy M. Weise and Lawrence E. Flaherty declare that they have no conflict of interest

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Karmanos Cancer Institute, 4100 John R. Rd., Detroit, MI, USA

    Amy M. Weise & Lawrence E. Flaherty

Authors
  1. Amy M. Weise
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lawrence E. Flaherty
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amy M. Weise.

Additional information

This article is part of the Topical Collection on Melanoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weise, A.M., Flaherty, L.E. New Options for the Adjuvant Treatment of Cutaneous Melanoma?. Curr Oncol Rep 16, 409 (2014). https://doi.org/10.1007/s11912-014-0409-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-014-0409-x

Keywords

Search

Navigation